LEADER 05428nam  2200709   450 
001 9910464469103321
005 20211005210640.0
010   $a0-19-103388-X
010   $a0-19-172637-0
035   $a(CKB)3410000000001995
035   $a(EBL)1692723
035   $a(SSID)ssj0000627934
035   $a(PQKBManifestationID)12229091
035   $a(PQKBTitleCode)TC0000627934
035   $a(PQKBWorkID)10701496
035   $a(PQKB)10244247
035   $a(StDuBDS)EDZ0000039282
035   $a(MiAaPQ)EBC1692723
035   $a(StDuBDS)EDZ0000091459
035   $a(Au-PeEL)EBL1692723
035   $a(CaPaEBR)ebr11198501
035   $a(OCoLC)923708559
035   $a(MiAaPQ)EBC5746283
035   $a(EXLCZ)993410000000001995
100   $a20170109h20112011  uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aOxford handbook of practical drug therapy /$fDuncan Richards [and three others]
205   $aSecond edition.
210  1$aNew York, [New York] :$cOxford University Press,$d2011.
210  4$d©2011
215   $a1 online resource (818 p.)
225 1 $aOxford handbooks
300   $aIncludes indexes.
311   $a0-19-956285-7 
327   $aCover; Contents; Symbols and abbreviations; How to use this book; Introductory sections; Prescribing; The drug history; Writing a prescription; Generic drugs and biosimilars; Repeat prescriptions; 'Off-licence' drugs; Cautionary and advisory labels; Some basic concepts; The World Health Organization (WHO) essential medicines list; Compliance, adherence, and concordance; Guidelines; Dose-response curves (concentration-effect curves); Efficacy of drugs; Adverse drug reactions; Drug-drug interactions; Placebos; Changing the doses of drugs; Renal insufficiency; Hepatic insufficiency
327   $aAn approach to rational prescribingPaediatric prescribing; Drugs and pregnancy; Drug therapy and breastfeeding; Drug development; 1 Gastrointestinal system; Gastric acid suppression; Histamine H[sub(2)] receptor antagonists: BNF 1.3.1; Proton pump inhibitors (PPIs): BNF 1.3.5; Misoprostol: BNF 1.3.4, 10.1.1; Drugs affecting gastrointestinal motility; Constipation: BNF 1.6; Co-phenotrope (Lomotil[sup(®)]): BNF 1.4.2; Loperamide (Imodium[sup(®)]): BNF 1.4.2; Inflammatory bowel disease; Mesalazine and related compounds (aminosalicylates): BNF 1.5; Sulfasalazine: BNF 1.5.1 and 10.1.3
327   $aLiver, biliary system, and lipidsCholic acids: BNF 1.9.1; HMG CoA reductase inhibitors ('statins'): BNF 2.12; Ezetimibe: BNF 2.12; Fibrates: BNF 2.12; Obesity; Orlistat: BNF 4.5.1; Antiemetics; Metoclopramide: BNF 4.6; Prochlorperazine (Stemetil[sup(®)]): BNF 4.6; Domperidone: BNF 4.6; Serotonin 5-HT[sub(3)] receptor antagonists: BNF 4.6; 2 Cardiovascular system; A pharmacological approach to the treatment of arrhythmias: BNF 2.3.1; Antiarrhythmic drugs; Adenosine: BNF 2.3.2; Flecainide BNF: 2.3.2; Cardiac glycosides (digitalis): BNF 2.1.1, 2.3.1, and 2.5.5; Disopyramide: BNF 2.3.2
327   $aAmiodarone: BNF 2.3.2 and 2.7.3Anticoagulants, antiplatelet drugs, and fibrinolytic drugs; Heparins (unfractionated and low molecular weight): BNF 2.8.1; Direct thrombin inhibitors: BNF 2.8.2; Fondaparinux sodium: BNF 2.8.1; Warfarin: BNF 2.8.2; Acetylsalicylic acid (aspirin): BNF 2.9 and 4.7.1; Clopidogrel: BNF 2.9; Dipyridamole: BNF 2.9; Glycoprotein IIb/IIIa antagonists: BNF 2.9; Fibrinolytic drugs: BNF 2.10.2 and 13.11.7; Ischaemic heart disease; Pharmacology of drugs used to treat acute coronary syndromes, including myocardial infarction: BNF 2.10
327   $aPharmacology of drugs used to treat heart failureNitrate drugs: BNF 2.6.1; Nicorandil: BNF 2.6.3; Beta-adrenoceptor antagonists ('beta-blockers'): BNF 2.4, 2.5.5, 6.2.2, 4.7.4, 11.6; Angiotensin converting enzyme inhibitors (ACE inhibitors): BNF 2.5.5.1; Angiotensin receptor antagonists/blockers (ARBs): BNF 2.5.5.2; Hypertension; An approach to the treatment of hypertension: BNF 2.5; Methyldopa (alpha-methyldopa): BNF 2.5.2; Calcium channel blockers; Calcium channel blockers (see also individual sections): BNF 2.6.2; Dihydropyridines (nifedipine-like): BNF 2.6.2
327   $aBenzothiazepines (diltiazem): BNF 2.6.2 and 2.3.2
330   $aSafe and effective prescribing is a cornerstone of proper patient care. There has in recent years been a significant increase in the numbers of healthcare professionals able to prescribe; however, sources of drug information tend to focus on only one area of prescribing. The Oxford Handbook of Practical Drug Therapy links practical information about how to use medicines with concise details about the pharmacology of a drug, and the principles of clinical pharmacology thatgovern its action.The overall structure of this handbook is similar to the UK national formulary, with topics on each drug a
410  0$aOxford handbooks.
606   $aDrugs$xPrescribing$vandbooks, manuals, etc
606   $aChemotherapy
606   $aPharmacology
608   $aElectronic books.
615  0$aDrugs$xPrescribing
615  0$aChemotherapy.
615  0$aPharmacology.
676   $a615.1
702   $aRichards$b Duncan
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910464469103321
996   $aOxford handbook of practical drug therapy$92052621
997   $aUNINA